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Background: The glycopeptide antibiotics vancomycin and teicoplanin are 
currently the last line of defence against some microorganisms that are resistant 
to many drugs. The emergence of vancomycin-resistant and teicoplanin-resistant 
enterococci underscores the need for more potent antibiotics. The glycosylation 
patterns of glycopeptides and chemical modifications of the glycosyl moieties 
have been shown to greatly influence their antibiotic activity, and certain 
combinations have resulted in highly active new compounds. To explore further 
the production of more potent glycopeptide antibiotics, we assessed whether 
glycosyltransferases could be used to produce hybrid compounds that contain 
various combinations of sugars and peptide cores. 
Results: We cloned five glycosyltransferase genes from Amycolatopsis 
orientalis strains that produce vancomycin or a related glycopeptide, A82846. 
The gtfB and gtfE’genes from A. orientalis strains expressed in Escherichia co/i 
produced glucosyltransferase activities that added glucose or xylose to the 
vancomycin heptapeptide. The GtfE’ protein added glucose efficiently to two 
other heptapeptides related to teicoplanin to produce hybrid glycopeptide 
antibiotics. The cloned gtfE’ gene, driven by the strong constitutive promoter 
ermEp*, was introduced into Streptomyces toyocaensis, which produces the 
antibiotic A47934, a heptapeptide related to teicoplanin; recombinant organisms 
produced glucosyl A47934, a hybrid glycopeptide antibiotic. 
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Conclusions: Cloned glycosyltransferases from glycopeptide antibiotic 
producers can be used to produce novel hybrid antibiotics, both in vitro and in 
viva. Because similar enzymes have differing degrees of substrate specificity, it is 
advantageous to characterize the substrate specificity with enzymes expressed 
in E. co/i prior to constructing recombinant actinomycetes for production. 
Introduction 
The glycopeptide antibiotics vancomycin and teicoplanin 
are important for the treatment of infections caused by 
Gram-positive bacteria. The glycopeptide vancomycin is 
the drug of choice for the treatment of infections caused 
by methicillin-resistant Staphylococcus awew [ 11. The gly- 
copeptide antibiotic A82846B [Z], which shares the hep- 
tapeptide core of vancomycin but contains three sugars 
rather than two as found in vancomycin (Fig. l), has been 
chemically modified at the amino position of the epi- 
vancosamine in the disaccharide moiety to generate novel 
glycopeptides that are active against vancomycin-resis- 
tant enterococci [3,4]. One or more of these compounds 
may be clinically useful in treating these otherwise often 
fatal infections. 
There are a number of glycopeptide antibiotic structures 
that differ in the heptapeptide or sugar residues [S]. 
Because antibiotics of the vancomycin/A82846B and 
teicoplanin types differ substantially in their heptapeptide 
cores and glycosylation patterns (Fig. 1) [5,6], it would be 
interesting to explore the production of hybrid glycopep- 
tides containing different combinations of heptapeptide 
and sugars to provide novel starting materials for chemical 
modification. In fact, two ‘glycopeptides’ of the teicoplanin 
heptapeptide class that lack sugar residues have been iden- 
tified, namely A47934 [7] and A41030A [8]. Interestingly, 
both molecules have very good antibacterial activities in 
vitro against Gram-positive pathogens, including S. aureus, 
Streptococcus pyogenes and Enterocoms faecalis [?I]. The 
microorganisms that produce these antibiotics, Streptomyces 
virginiae (A41030) and Streptomyces toyocaensis (A47934) are 
therefore potential hosts for the production of novel gly- 
copeptides related to teicoplanin. We have previously 
shown that S. toyocaensis is a suitable host for gene cloning 
[9]. We report here the cloning of two glycosyltransferase 
genes from the vancomycin producer Amycolatopsis orien- 
tal& C329.4, and three glycosyltransferase genes from the 
A82846B producer, A. orientalis A82846, and describe the 
use of these genes to produce hybrid monoglycosylated 
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Figure 1 
Glycopeptide structures. 
Vancosamine or 
N-Acyl glucosamine 
OH 
Vancomycln: RI =OH, Rz=Rs=H 
A82846B: RI =H, Rg=OH, R3=eplvancosaminyl 
Teicoplanln AZ-2 
Desvancosaminyl vancomycin (DVV): R=D-glucosyl 
Aglycosyl vancomycin (AGV): R=H 
Xylosyi AGV: R=D-xylosyl 
A41030A: R, =R,=H 
A47934: R, =SO,, R,=H 
Glucosyl A41030A: R, =H, Rp=D-glucosyl 
Glucosyl A47934: R, =SO,, Rg=D-glucosyi 
glycopeptides derived from A4103OA, A47934 and the van- 
comycin core, both Zn aitro and in a& in a recombinant 
S. to~caensis strain. 
Results and discussion 
Cloning and sequence analysis of five glycosyltransferase 
genes from microorganisms that produce glycopeptide 
antibiotics 
A series of polymerase chain reactions (PCR) was used 
to isolate DNA fragments containing glycosyltransferase 
genes from A. orient& C329.4 and A. otientulis A82846 
(see the Materials and methods section). DNA analysis for _ - 
open reading frames (ORFs), analysis of the GC content 
of the codons [lo], and comparison of the predicted genes 
to the nonredundant GENEMBL database, suggested 
that a 5.7 kilobase (kb) BglrI restriction fragment isolated 
from A. orZent& A82846 contained three glycosyltrans- 
ferase genes, &A, g@R, and gtj??, and the 5.7 kb RgAI 
restriction fragment isolated from A. orientulis C329.4 con- 
tained two glycosyltransferase genes, gtiD and g@E (Fig. 
2). The glycosyltransferases had amino-acid identities that 
ranged from 57% to 82% (Figs 2,3) and were flanked by 
ORFs homologous to hydroxylases that had about 93% 
amino-acid identities (Fig. 2). The glycosyltransferasc 
encoded by the ~JLE gene appeared to be the TDP- 
glucose:aglycosyl vancomycin glucosyltransferase on the 
basis of its identity to the amino-terminal amino-acid 
sequence of this enzyme (M. Zmijewski and B. Briggs, 
personal communication). The gjrfB gene from A. o~.lent~/jJ 
A82846 appeared to encode an enzyme with the same 
function because GtfE had a higher percentage amino- 
acid sequence identity to GtfB (82%) than to GtfA (63%) 
or GtfC (64%; Fig. 2). In addition, the higher percentage 
amino-acid sequence identity of GtfC to GtfD (69%) than 
GtfA to GtfD (57%; Fig. 2) suggested that the Gtf(: and 
GtfD proteins may have similar functions, namely the 
addition of epivancosamine or \.ancosamine to glucose in 
the biosynthesis of A82846 or vancomycin. Because GtfA 
is the least similar to the other glycos)rltransferascs, it may 
add the third sugar (epivancosamine) to A82846 (Fig. 1). 
Enzymatic glycosylation of glycopeptide aglycones in vitro 
The in vitro glycosylation reactions arc summarized in 
Figure 4. The GtfB and GtfE’ enzymes expressed in 
Escherirhia co/i added glucose to aglycosyl vancomycin 
(AGV) [ll] in the presence of TDP-glucose in h-o to 
produce desvancosaminyl vancomycin (DL’V) [ 111, estab- 
lishing that these enzymes are glucosyltransferases 
(Fig .ja,e). (GtfE’ is a variant of GtfE with a single serine- 
for-proline substitution (Fig. 3) produced by a mutation 
introduced by PCR amplification of the gene.) GtfA and 
GtfC did not produce a glucosylated product in similar 
reactions. IJDP-glucose appeared to function as \vell as 
TDP-glucose as a sugar donor for both GtfB and GtfE’ 
(data not shown). GtfE’ also added glucose rclativcly effi- 
ciently from TDP-glucose or IYDP-glucose to alternative 
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Figure 2 
The percentage of identical amino acids in the 
glycosyltransferases and proteins encoded by 
the flanking genes. (a) The 5.7 kb Bgill 
fragment from A. orientalis A82846UV37B. 
(b) The 5.7 kb Bglll fragment from A. 
orientalis C329.4 (see text for details). The 
nucleotide sequences have been assigned 
Genbank accession numbers U84349 and 
U84350. 
(a) Hydroxylase gtfA gtfB gtfC Hydroxylase 
r-l h 
i/ I 
(b) 
h i\ 
7 I/ 
Hydroxylase Hydroxylase gtfD gtfE Hydroxylase 
1000basepa1rs 
heptapeptide cores, A47934 and A41030A, as determined containing GtfI3, A41030 and TDP-I)-glucose resulted in a 
by high performance liquid chromatography (HPLC; small peak when analyzed by HPLC, which appeared to be 
Fig. Sb,c,f,g) and mass spectroscopy (data not shown). The glucosyl A41030. GtfB did not appear to glucosylate 
purified glucosyl A41030A and glucosyl A47934 had A47934. It \vas surprising that GtfE’ much more readily 
antibacterial activity against Illi~r~coc~us luteus. A reaction glucosylated an alternative heptapeptide substrate than did 
Figure 3 
1 105 
GtfB SARAPIQRA.. 
GtfE SARPSAGQA.. 
GtfC LEGMLLQEGM 
GtfD .aHMMLQEGM 
GtfA VRAZAREPGE 
c3lls 
PSTQDT 
PPAPDG 
RTTPGV 
PTTPGV 
GtfB 
GtfE 
GtfC 
GtfD 
GtfA 
cons -D---“QTG-WIL-D-RP---EL-ApL-AG--pV--GpGS------ -DA---A----RA-G-R-- 
316 
GtfB 
GtfE 
GtfC 
GtfD 
GtfA 
COn* 
PILEUP of glycosyltransferase amino-acid sequences. Amino acids (cons) line. An arrow (J) indicates the position of the proline-to-serine 
occurring in at least four of five sequences are highlighted. Amino mutation in GtfE’. Numbering refers to the number of characters per 
acids occurring in five of five sequences are listed on the consensus line and does not take into account the gaps. 
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Figure 4 
Glucosyltransferase o 
NDP-sugar 
* 
no 
Heptapeptide N DP-sugar GtfE GtfB 
AGV TDP-D-glucose + + 
UDP-D-glucose + + 
UDP-D-xylose + + 
UDP-D-galactose 
UDP-D-mannose 
UDP-IV-acetylglucosamine - 
UDP-galacturonic acid 
A41 030A 
A47934 
TDP-D-glucose + (+) 
UDP-D-glucose + NT 
TDP-o-glucose + 
UDP-o-glucose + NT 
Summary of in vitro glycosylation reactions 
using GtfE’ or GtfB. Symbols: +, 25-75% 
conversion to glycosylated product; (+), < 2% 
conversion to glycosylated product; -, no 
conversion observed. NT, not tested; AGV, 
aglycosyl vancomycin. 
Figure 5 
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HPLC profiles of glycosylation reactions. (a-c) In vitro reactions A47934 and TDP-glucose with GtfE’ expressed in E. co/i. 
containing aglycosyl vancomycin (AGV), A41 030A or A47934 and (h) S. toyocaensis A47934::pCZA345 fermentation. The AGV 
TDP-glucose without E. co/i lysate. (d) S. toyocaensis A47934 standard used in (a) and (e) contained a small amount of 
fermentation. (e-g) In vitro reactions containing AGV, A41 030A or desvancosaminyl vancomycin (DVV). 
Research Paper Hybrid glycopeptide antibiotics Solenberg et al. 199 
Table 1 
Strains and plasmids. 
Strains and plasmids 
E. co/i DH5alpha 
E. co/i XL-l Blue 
E. co/i s17-1 
E. co/i BL21 (DE3) 
A. orientabs A02846 
A. orientalis A82846UV376 
A. orientalis C329 
A. orient& C329.4 
S. toyocaensis A80934 
S. virginiae A41 030 
pCR-Script SK(+) 
PET-1 la 
PET-1 6b 
plJ2926 
plJ4070 
pCZA299 
pCZA301 
pCZA3 18 
pCZA3 19 
pCZA333 
pCZA334 
pCZA338 
pCZA339 
pCZA344 
pCZA345 
pCZA361 
pCZA362 
pCZA363 
pOJ436 
pSETl52 
pZErO-1 
Description 
F- endA hsdR17 (rk-) supE44 thi-7 A- recA1 deoR 
gyrA96 relA7 A (argF-/acZYA) U169 $80dlacZAM15 NalR 
recA1 endA gyrA96 tbi-7 hsdRl7 supE44 reelA lac [F’ proA lacPZAM15 
Tn 7 0 Tetr)l 
C600::RP4 2-Tc::Mu-Km::Tn7hsdR hsdM+recA 
F- ompT re- ma- DE3 lysogen 
Produces glycopeptide A82846 
Enhanced producer of A828468 
Produces vancomycin 
Produces elevated quantity of vancomycin 
Produces glycopeptide A47934 
Produces glycopeptide A41 030A 
PCR fragment cloning vector 
E. co/i expression vector 
E. co/i expression vector, adds purification handle 
pUCl9 derivative containing Bglll sites flanking the multiple cloning site 
plJ2926 derivative containing ermEp* promoter 
plJ2926 derivative containing A. orientalis A82846lJV37B 5.7 kb 89111 
fragment with gtfA, gtfB and gtfC 
pOJ436 derivative containing A. orientalis A82846UV37B gtfA, gtfB and gtfC 
PET-1 1 a containing gtfB 
pZErO-1 containing A. oriental& C329.4 gtfA and gtfB 
pSETl52 derivative containing @,(ermEp*-gtf6) (pLac reading against gtf6) 
pSETl52 derivative containing @(ermEp*-gtf6) (pLac reading with gtfB) 
PET-1 1 a containing gtfE’ 
pSETl52 derivative containing A. orientalis C329.4 gtfD and gtff 
pSETl52 containing @(ermEp*-gtfE’) (pLac reading with gtfE’) 
pSETl52 containing @,(ermEp*-gtfE’) (pLac reading against gtfE’) 
Cosmid containing glycosyltransferase genes on 38 kb A. orientalis 
A82846UV37B genomic fragment 
Cosmid containing glycosyltransferase genes on 33 kb A. orientalis 
A82846lJV37B genomic fragment 
Cosmid containing glycosyltransferase genes on 41 kb A. orientalis 
A82846UV37B genomic fragment 
Cosmid cloning vector, $C31 a#‘, oriT 
integrating plasmid, $C31 attP, or;;iT 
E. co/i cloning vector 
Source/reference 
Gibco BRL 
Stratagene 
E51 
Novagen, 1261 
NRRL 18098 
Lilly culture collection 
NRRL 2452 
Lilly culture collection 
[71 
[81 
Stratagems 
Novagen 
Novagen 
WI 
M.J. Bibb 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
This work 
[I91 
1191 
lnvitrogen 
GtfB, because these enzymes have a high degree of amino- 
acid identity and have the same natural substrates. The dif- 
ference in activity between GtfB and GtfE’ cannot be 
attributed to the single amino-acid difference in GtfE’ 
because native GtfE from A. orientah C329.4 glucosylated 
A47934 and A41030 relatively efficiently [12]. 
Both GtfB and GtfE’ converted -25% of AGV to xylosyl 
AGV as confirmed by HPLC and mass-spectrometry 
analysis when LJDP-I>-xylose was substituted for TDP- 
glucose in the assay (data not shown). The xylosyl AGV 
product had antibacterial activity against M. Iutezds. Gly- 
cosylated products of AGV were not observed when IJDP- 
I)-galactose, LJDP-[I-mannose, UDP-II-galacturonic acid 
or UDP-AT-acetylglucosamine were used as sugar donors. 
Interestingly, mannose and galactose differ from glucose 
only in the stereochemistry of one hydroxyl group, 
whereas xylose has the same stereochemistry as glucose 
but lacks a hydroxymethyl substituent. 
Production of a hybrid glycopeptide antibiotic by a 
genetically engineered strain of S. foyocaensis 
We recently developed a gene-cloning system for S. to-y- 
ocaensis [9] that uses conjugal vectors that integrate site- 
specifically into the bacteriophage $C31 attB site without 
disrupting A47934 production. 11. orientalis C329.4 and 
A82846UV.?7B DNA that contained glycosyltransferase 
genes was introduced into S. toyocaensis to determine 
whether glucosylation of A47934 would occur in Go. S. toy- 
ocaensis A80934 containing cosmids pC7,A361, pCZA362 
and pCZA363 (Table 1 and the Materials and methods 
section) integrated into the chromosome did not appear to 
produce a new compound as determined by HPLC analy- 
sis. In addition, new compounds were not seen from S. tsy- 
ocaensis clones containing the g@l, gt$B, and ,&c genes from 
A. orientalis A82846 on the integrating plasmid pCZA301 or 
the gfl and gfl genes from A. orientalis C329.4 on the 
integrating plasmid pCZA339. When the strong constitu- 
tive ermEp* promoter was inserted in front of g@E’ on 
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plasmids pCZA344 and pCZA345 and these plasmids were 
inserted into the 4C31 URB site of S. tc?yomensi.r, however, a 
new peak with antibacterial activity was observed after fer- 
mentation that had the same HPLC retention time as glu- 
cosyl A47934 (Fig. Sd,h). A new peak was not observed 
using similar constructs containing the x~B gene (plasmids 
pCZA333 and pCZA334). 
These results suggest that a promoter is not present on the 
and possibly other glycosyltransferase genes may allow 
DNA fragments used for expression of the glycosyltrans- 
ferases, or that the natural d. orientnl?.~ promoter(s) are 
the production of a wide array of novel glycopeptide 
not recognized by S. tqyouwzsis, since ermEp* was needed 
antibiotics which can serve as starting materials for further 
to obtain a glycosylated product. The in aivo results also 
agree with the in vitro results indicating that the GtfE’ 
enzyme more readily accepts the A47934 substrate than 
the GtfB enzyme. Because GtfB and GtfE have 82% 
chemical modification. 
amino-acid identity, these glucosyltransferases should be 
useful in exploring the amino-acid sequences involved 
in determining the specificity of glycopeptide substrate 
recognition. Furthermore, the five cloned glycosyltrans- 
ferasc genes can be used to determine the regions involved 
in substrate and cofactor specificity, and will provide the 
starting materials for further biosynthesis of novel gly- 
copeptides. By the production of glucosyl A47934, glucospl 
A4103OA, and xylosyl AG\‘, we have shown that hybrid 
glycopeptide antibiotics can be produced in vitro and in 
oivo using cloned glycosyltransferase genes. [‘SC of these 
Materials and methods 
Bacterial strains, culture conditions and compounds 
Bacterial strains used tn this study are listed in Table 1. The actlno- 
mycete and E. co/i cultures were grown in TSB and TY broth respec- 
tively [13]. Compounds A47934, A41 030A, AGV and apramycin were 
obtained from Eli Lilly and Co. Nucleotide-sugars were purchased 
from Sigma Chemical Co. The isolated compounds were tested for 
antibacterial activity by resuspending a small amount of the compound 
in water, avd spotting on TY agar [131 seeded with M. luteus. After 
incubati6n overnight at 37°C the plates were checked for a zone of 
growth inhibition. 
DNA cloning, amplification and sequencing 
DNA cloning and f. co/i transformations were performed as described 
PCR and sequencing primers were synthesized using an Applied 
[141. Plasmids were introduced by transformation or by conjugation 
from E. co/i Sl 7-l to S. toyocaensis as described [9]. Plasmid DNA 
Biosystems 380B oligonucleotlde synthesizer (PE-ABI) or obtained 
was isolated from E. co/i using Cliagen columns (Qiagen, Inc.) accord- 
from Genosys Biotechnologies, Inc. DNA fragments were either cloned 
ing to the manufacturer’s protocol. Genomic DNA was isolated from 
actinomycetes as described [151. DNA fragments were purified from 
and sequenced or sequenced directly after gel isolation by Dye Termi- 
gels using Gene Clean II (Bio 101, Inc.) except for the 84 base-pair 
nator chemistry using a PRISM cycle sequencing Ready Reaction Kit 
(bp) fragment which was purified using Mermaid (Bio 101, Inc.). South- 
ern hybridizations were as described [16]. Restriction enzymes, alkaline 
(PE-ABI). Reactions were cycled using 96% for 1 min followed by 25 
phosphatase and DNA polymerase were used according to the suppli- 
ers specifications; 3% Nusieve 3:l agarose gels (FMC) were used for 
the analysis of DNA fragments <1 kb in size. The thermocycling pro- 
cedure for PCR reactions consisted of 99% for l-5 min, 80°C for suf- 
ficient time to add the DNA polymerase [17] followed by 30 cycles 
of amplification (95” or 96°C for 3Os, annealing temperatures ranging 
from 62”-68” for 3Os, followed by 72°C for l-2 min). Touchdown 
PCR [18] was used for heterologous or degenerate primers. Stoffel 
DNA polymerase (Perkin Elmer) was used for PCR amplification unless 
otherwise indicated. Broth culture (2 ~1) and Gene ReleaserTM (BioVen- 
tures, Inc.) was used for PCR amplification from the cosmid library. 
Significance 
This work describes the first use of cloned and 
expressed glycosyltransferase genes to produce hybrid 
glycopeptide antibiotics. Enzymatic glycosylation allows 
us to produce specific glycopeptides, a process that is dif- 
ficult to perform by chemical synthesis. Glyco- 
syltransferases have some flexibility in their substrate 
specificity, however, making it possible to synthesize 
hybrid glycopeptide antibiotics that differ in their sugar 
content or peptide cores. 
The expression of the glycosyltransferase in E. coli and 
the use of an active enzyme extract to glycosylate in vitro 
allows sugar or peptide core substrates that do not occur 
naturally in a particular host organism to be used. The 
expression of a glycosyltransferase in a recombinant host 
that produces the core peptide makes possible the pro- 
duction of the hybrid antibiotic during growth of the 
organism, and there is potential for production on a 
larger scale. The use of additional glycosyltransferases 
and modification of these enzymes by manipulating the 
domains that contribute to substrate specificity may 
make possible the enzymatic synthesis of a wide variety 
of glycosylated antibiotics. 
cycles of 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. Gel prepara- 
tion, electrophoresis, and data collection using a Model 377 DNA 
Sequencer (PE-ABI) were according to the manufacturer’s protocol. 
The 5.7 kb Bg/ll fragment from A. orientalis A82846 was sequenced by 
Beksan Ltd. Sequence comparison and analysis was performed using 
the Wisconsin Package (Genetics Computer Group). 
Preparation of the cosmid library 
A cosmid library of A. orient& A82846U1/376 was prepared essen- 
tially as described for a two-cos system [13]. Cosmid vector pOJ436 
[19] was digested with Hpal, treated with calf alkaline phosphatase, 
and then digested with BarnHI. A82846U1/376 DNA embedded in soft 
agarose [20] was partially digested with Sau3A to yield the maximum 
amount of 38-50 kb fragments. The Sau3A fragments were ligated 
with the BarnHI-digested pOJ436 and packaged with Gigapack II-XL 
(Stratagene) lambda extracts according to the supplier’s protocol. 
After infection, 1152 E. co/i XL-1 Blue colonies containing cosmids 
were inoculated into individual wells in 12 96.well microtiter plates and 
into wells of a deep 96.well plate so that each deep well was inocu- 
lated with 12 colonies from one row of the microtiter plate. The plates 
containing two-times concentrated TY broth [131 with 100 pg ml-’ 
apramycin were sealed and incubated overnight at 37°C with gentle 
shaking. Glycerol was added to 20% final concentration and the library 
was stored at -70°C. 
Isolation of glycosyltransferase genes from A. orientalis 
A82846UV37B and A. orientalis C329.4 
PCR primers PJS49 (5’ACITGYGGITCICGIGGIGACGTIGARCC3’) 
and PJS50 (5’CATCATlCGlACYTClGClCCRCAYTC3’) were designed 
by back-translation of the 33 amino-acid amino-terminal sequence 
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(M. Zmijewski and B. Briggs, personal communication) of the TDP- 
glucose:aglycosyl vancomycin glucosyltransferase isolated from A. orien- 
talk C329 [21]. Primers contained deoxyinosine or were degenerate at 
several of the ambiguous codon positions [221. PCR reactions contain- 
ing A. orientalis C329.4 genomic DNA, but not A82846W37B genomic 
DNA, successfully amplified a 84 bp PCR product using primers PJS49 
and PJS50 and Taq DNA polymerase (BRL). The 84 bp product was 
sequenced, and the 28 bp amplified between the primer sequences 
encoded amino acids that agreed with the amino-terminal amino-acid 
sequence (data not shown). A new primer, PJS72 (5’GARCCACTGGT. 
GGCGTTGGCGGT3’) was designed for amplification of the down- 
stream region of the glucosyltransferase based on the 28 bp sequence. 
In addition, a search of a nonredundant Genbank and EMBL databases 
as of February 8, 1994 using TBLASTN [23] with the 33 amino-acid 
amino-terminal sequence found two sequences that had similarity at their 
amino-terminal ends. These sequences encoded a rhamnosyltransferase 
from Pseudomonas aeruginosa (accession number L28170) and a hypo- 
thetical protein from /L?ycobacterium leprae (accesslon number UOO023). 
Conserved amino acids in these two sequences, which had 25% identity 
to each other, were used to design a series of 10 downstream primer 
sequences (not shown). PCR amplification using primers PJS49 and 
PJS57 (5’GGIACTCCGGCCCTIAGGCTlGClGClGTlGTlCClGCGC- 
ClCCRTG3’), and reamplification two times using primers PJS72 and 
PJS57, resulted in a 950 bp fragment amplified from A. orientalis C329.4 
which encoded an amino-acid sequence with about 27% identity to the 
P. aeruginosa and M. leprae sequences. Several primers (not shown) 
were designed based on amino acids conserved between the three 
sequences. Of these, primers PJS86 (5’TTGCGGGAGCGCGGCGG 
CGAGGT3’) and PJS92 (5’CCGGCGTCCAGGAACGCCTCCAGC 
TC3’) amplified a band from A. orientalis A82846UV375 genomic DNA. 
Using these primers, PCR amplification of a A. orientalis A82846UV37B 
cosmid library (pools of clones then individual clones) was used to iden- 
tify three cosmids, pCZA361, pCZA362 and pCZA363, containing gly- 
cosyltransferase genes. Cosmid pCZA361 contained -38 kb of genomic 
DNA and extended downstream of the glycosyltransferase genes. 
Cosmid pCZA363 contained -41 kb of genomic DNA and extended 
upstream of the glycosyltransferase genes. Cosmid pCZA362 contained 
-33 kb and is a subset of cosmid pCZA363. Cosmids pCZA363 
and pCZA361 had -6.5kb of genomic DNA in common and together 
represent coverage of -72 kb of the genome. 
The 950 bp fragment amplified from A. orientalis C329.4 hybridized 
to 5.7 kb Bgill fragments from cosmid pCZA361 and both A. orientalis 
A82846UV375 and A. orientalis C329.4 genomic DNA. Cosmids 
pCZA362 and pCZA363 contained larger hybridizing fragments. The 
5.7 kb BgWfragment from pCZA361 was cloned into the BamHl site of 
plJ2926 [24] resulting in plasmid pCZA299 and was sequenced by 
Beksan Ltd. 
C329.4 genomic DNA (20 pg) was digested with Bg/ll and the resulting 
DNA fragments were separated on a 0.75% agarose gel. The gel, con- 
taining DNA fragments ranging in size from - 5.0-6.5 kb, was sliced into 
four pieces containing pools of similar sized DNA fragments. DNA from 
the four pools was used as a template in PCR reactions containing 
primers PJS86 and PJS92. The pool of DNA which gave a PCR-ampli- 
fied band at the expected size of 650 bp was cloned into BarnHI- 
digested pZErO-1 (Invitrogen), according to the manufacturer’s protocol. 
PCR using the same primers and -25% of a transformed colony as 
a source of template was used to identify one clone, pCZA319, of the 
50 tested, which contained a 5.7 kb fragment and gave an amplified 
fragment of 650 bp. 
Construction of plasmids 
PCZA299 was digested with Acsl and Narl and the 1.2 kb fragment 
containing gtf6 was subcloned into EcoRI- and Nail-digested pUCl9 
resulting in pCZA305; gffB was amplified by PCR using primers 
PJSI 15 (5’GGGAAGCTTCATATGCGTGTGCTGTTGGCGACGTG. 
TG 3’ and PJSl18 (5’GGGAGATCmACGCGGAAACAGTCGGCT- 
TTTCC3’) and UlTma DNA polymerase (Perkin Elmer) to add an Ndel 
site at the 5’ end and a Bgill site (italics) at the 3’ end of the gene. The 
blunt PCR product was cloned into pCR-Script SK(+) vector resulting 
in plasmid pCZA308. The Ndel to BamHl fragment of pCZA308 
encoding gtf5 was subcloned into PET-1 66 resulting In pCZA312. An 
Rsrll to Aadl fragment of pCZA312 (PCR-derived clone) was replaced 
with an Rsril to Aadl fragment of pCZA305 (genomically derived clone) 
resulting in plasmid pCZA315. This corrected three nucleotide errors 
that encoded amino-acid changes in the PCR-derived gtfB sequence 
that resulted in an inactive glycosyltransferase (data not shown). 
PCZA318 was constructed by cloning the 1.2 kb Ndel fragment from 
pCZA315 into the Ndel site of PET-1 la so that the T7 promoter on the 
plasmid could drive expression of the gtfB gene. 
PCZA319 was digested with Ncol and the 3.4 kb fragment containing 
gtfE was isolated and amplified by PCR in 10 separate reactions 
using primers PJS142 (5’GGGAAGCTTCATATGCGTGTGTTGTTG. 
TCGACC 3’) and PJSI 43 (5’GGGAGATCTTCAGGCGGGAACGG. 
CGGGCTGGT3’) and VentRR DNA polymerase (NEB) to add an 
Ndel site at the 5’ end and a Bglll site (italics) at the 3’ end of the 
gene. Nine of the ten reactions had fragments of -1250 bp. Frag- 
ments from five reactions were cloned into pCR-Script SK(+) and 
then subcloned on an Ndel- to Bg/l-fragment into Ndel- and Bglll- 
digested PET-1 1 a. In vitro glycosylatlon assays using AGV and TDP- 
glucose showed that one of these clones, containing plasmid 
pCZA338, expressed glucosyltransferase activity. 
PCZA338 was digested with Xbal and Hmdlll, and the -1.5 kb frag- 
ment containing gtfE’ was cloned into Xbal- and Hindlll-dlgested 
plJ4070 resulting in plasmid pCZA340. (The gtfE’ gene contained 
two PCR-induced mutations resulting in one amino-acid difference 
between GtfE and GtfE’). The 1.8 kb Bglll fragment of pCZA340 con- 
taining gtff’ downstream of ermEp* was cloned in both orientations 
into BarnHI-digested pSETl52 resulting in pCZA344 and pCZA345. 
Similarly, pCZA318 was digested with Xbal and Hmdlll and the -1.5 
fragment containing gtfB was cloned into &al- and Hindlll-digested 
plJ4070, resulting in plasmid pCZA329. The 1.8 kb Bglll fragment of 
pCZA329 containing gtfB downstream of ermEp* was cloned in both 
orientations into BamHI-digested pSETl52 resulting in pCZA333 
and pCZA334. 
PCZA299 was digested with Bglll and the fragment containing gtfA, 
gtfB and gtfC was cloned Into BarnHI-digested pOJ436, resulting 
in plasmid pCZA301. This plasmid was digested with Pvull and the 
-4.6 kb fragment containing gtfD and gtfE and the ORF upstream was 
cloned into EcoRV-digested pSETl52, resulting in pCZA339. 
In vitro glycosylation reactions 
An overnight culture of E. co/i BL21 (DE3) cells containing expression 
plasmids pCZA318 or pCZA338 (5 ml) was diluted into TY broth con- 
taining carbenicillin at 50 pg ml-’ and grown with shaking at 27°C to 
an boo of 0.4-l .O. The cells were Induced by adding isopropyl-P-o- 
thiogalactopyranoside (IPTG) to a final concentration of 1 mM and 
incubated for 2.5-3 h. The cells were pelleted and resuspended in 
0.1 vol of 50mM TRIS (pH 9.0). Lysozyme was added to 0.5mgml-’ 
and incubated for 10 min at room temperature. The cells were broken 
by sonication or by forcing them through a 23-gauge needle with a 
syringe several times. Aliquots of the lysate (2ml) were pelleted for 
1 min in a microfuge. The glycosylation reactions based on reactions 
previously described [21] contained l-2 mg of AGV, A41030A or 
A47934 dissolved in 50mM TRIS (pHQ.O), 3-5 mg of a nucleotide- 
sugar in 100 (11 H,O, 5 ~1 1 .O M dithiothreitol (DTT), 10 ~1 100 mg ml-’ 
bovine serum albumin (BSA) and about 585 ~1 of the cell supernatant. 
Reactions (1 ml) were incubated at 37°C with slow tumbling overnight. 
Reactions were filtered through an Acrodisc 13CR PTFE 0.45mM 
filter (Gelman) and then analyzed by HPLC and mass spectrometry. 
Fermentation of recombinant S. toyocaensis strains 
Recombinant S. toyocaensis strains were fermented on the glucose- 
containing medium SGCP for 7 days at 30°C. The fermentation medium 
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at pH 6.8-7.0 contained (per liter): glucose, 15 g; potato dextrin, 309; 
blackstrap molasses, 3.09; nutrisoy flour, 159; casein, 5.09; CaCO,, 
5.09. After fermentation the cells were pelleted and the supernatant 
was analyzed by HPLC. 
HPLC analysis and isolation of glycosylated compounds 
The in viva and in vitro glycosylations were monitored by analytical 
HPLC (reversed-phase) using a Waters FBondapak Cl8 column 
(3.9 x300mm) at a flow rate of 2 ml min-’ with UV detection at 280 nm. 
Elution was accomplished with a linear gradient of 5% CHsCN-95% 
buffer to 80% CHsCN-20% buffer over 30 min. The buffer used was 
0.5% triethylamine in water, adjusted to pH 3 with HsPO,. Purification 
of the glycosylated products was accomplished by semi-preparative 
HPLC using a Zorbax SB-Cl8 column (21.2x250 mm) at a flow rate 
of 15 ml min-1 and UV detection at 280 nm. Elution was accomplished 
with the same gradient/solvent system as described above. The 
desired fraction was desalted with a Waters Sep-Pak (12~~) then 
lyophilized to afford the product as a white powder. 
Electrospray LC/MS analyses 
Mobile phases consisted of O.lO/a (v/v) trifluoroacetic acid in water 
(Solvent A) and 0.1% trifluoroacetic acid (v/v) in acetonitrile (Solvent 
B). A linear gradient from 5-800/o Solvent B over 45 min at a flow rate 
of 1 mlmin-l was used. Peaks were detected at a wavelength of 
280 nm. A 20 PI min-l post-column split flow rate was delivered to the 
pneumatically assisted electrospray source of a PE-Sciex API Ill triple 
quadrupole mass spectrometer. Mass spectral analyses were per- 
formed in the positive ion detection mode over a range of 500-2000 u 
in 0.35 u intervals for a dwell time of 0.75 msec per interval. 
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